



SDI Review Form 1.6

Journal Name:	British Journal of Pharmaceutical Research
Manuscript Number:	2013_BJPR_5633
Title of the Manuscript:	Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy
Type of the Article	Research Paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments		
Optional/General comments	<p>This is an excellent paper analysing the incidence of psychiatric adverse events related to roflumilast use in patients with COPD. These are very rare but little is known on their risk factors. This paper attempts to discuss it based on spontaneously reported AEs and represents the basis for further research to further document them</p>	

Note: Anonymous Reviewer